HRP20170075T1 - Spoj benzotiazolona - Google Patents
Spoj benzotiazolona Download PDFInfo
- Publication number
- HRP20170075T1 HRP20170075T1 HRP20170075TT HRP20170075T HRP20170075T1 HR P20170075 T1 HRP20170075 T1 HR P20170075T1 HR P20170075T T HRP20170075T T HR P20170075TT HR P20170075 T HRP20170075 T HR P20170075T HR P20170075 T1 HRP20170075 T1 HR P20170075T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- acceptable salt
- pharmaceutically acceptable
- free form
- image
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011079379 | 2011-09-06 | ||
| PCT/IB2012/054580 WO2013035047A1 (en) | 2011-09-06 | 2012-09-05 | Benzothiazolone compound |
| EP12770249.6A EP2753609B1 (en) | 2011-09-06 | 2012-09-05 | Benzothiazolone compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170075T1 true HRP20170075T1 (hr) | 2017-03-24 |
Family
ID=47010668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170075TT HRP20170075T1 (hr) | 2011-09-06 | 2012-09-05 | Spoj benzotiazolona |
Country Status (39)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| SI2890687T1 (sl) * | 2012-08-30 | 2017-10-30 | Novartis Ag | Soli benzotiazolonske spojine kot agonist beta-2-adrenoceptorja |
| ES2646916T3 (es) | 2012-11-19 | 2017-12-18 | Bayer Pharma Aktiengesellschaft | Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa |
| WO2014132205A1 (en) | 2013-02-28 | 2014-09-04 | Novartis Ag | Formulation comprising benzothiazolone compound |
| US10967119B1 (en) | 2019-04-01 | 2021-04-06 | Azizi Bilal | Wearable medication injecting device |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE149089T1 (de) * | 1987-09-15 | 1997-03-15 | Rowett Research Inst | Anwendungsgebiete von beta-adrenergenen agonisten |
| US20070082918A1 (en) * | 1993-11-02 | 2007-04-12 | Naftchi N E | Neurologically active compounds and compounds with multiple activities |
| GB9405019D0 (en) | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| WO1999009018A1 (en) | 1997-08-14 | 1999-02-25 | Kirin Beer Kabushiki Kaisha | BENZOTHIAZOLONE DERIVATIVES HAVING SELECTIVE β2 RECEPTOR AGONIST ACTIVITY |
| EP1144387A1 (en) | 1998-12-04 | 2001-10-17 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6872723B2 (en) * | 2002-01-28 | 2005-03-29 | Wyeth | Stabilized difloxacin injectable solution |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US6743797B2 (en) * | 2002-02-22 | 2004-06-01 | Chantest, Inc. | Methods for treating cardiac arrhythmia |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| CA2520030A1 (en) * | 2003-03-26 | 2004-10-07 | Pharmacia & Upjohn Company Llc | Process to produce enantiomerically enriched alcohols and amines |
| ATE421322T1 (de) * | 2003-04-04 | 2009-02-15 | Novartis Pharma Gmbh | Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege |
| EP1635800A2 (en) | 2003-06-10 | 2006-03-22 | Kalypsys, Inc. | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease |
| JP2007503472A (ja) * | 2003-06-10 | 2007-02-22 | カリプシス・インコーポレーテッド | 病気治療用のヒストン脱アセチル化酵素阻害剤としてのカルボニル化合物 |
| EP1643974A1 (en) | 2003-07-11 | 2006-04-12 | Glaxo Group Limited | Inhalable pharmaceutical formulations comprising a sugar ester |
| EP1646370A1 (en) | 2003-07-11 | 2006-04-19 | Glaxo Group Limited | Pharmaceutical formulations |
| ES2329586T3 (es) | 2003-11-21 | 2009-11-27 | Theravance, Inc. | Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino. |
| GB0328490D0 (en) | 2003-12-09 | 2004-01-14 | Glaxo Group Ltd | Medicinal compounds |
| JP2005187357A (ja) | 2003-12-25 | 2005-07-14 | Nippon Suisan Kaisha Ltd | 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法 |
| GB0402797D0 (en) | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
| WO2005110990A1 (de) | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen |
| EP1595873A1 (de) | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen |
| JP2008507532A (ja) | 2004-07-21 | 2008-03-13 | セラヴァンス， インコーポレーテッド | ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト |
| DE102004045648A1 (de) | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| GB0426164D0 (en) * | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| DE102005007654A1 (de) | 2005-02-19 | 2006-08-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
| TW200738659A (en) | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200740781A (en) | 2005-08-29 | 2007-11-01 | Astrazeneca Ab | Novel compounds |
| WO2007086078A2 (en) | 2006-01-30 | 2007-08-02 | Panacea Biotec Ltd. | Novel pharmaceutical compositions and process of preparation thereof |
| BRPI0707719A2 (pt) | 2006-02-10 | 2011-05-10 | Summit Corp Plc | uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo |
| TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| GB0613154D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| MX2009001534A (es) * | 2006-08-10 | 2009-04-08 | Us Gov Health & Human Serv | Preparacion de (r,r)-fenoterol y analogos de (r,r)- o (r,s)-fenoterol y su uso en el tratamiento de insuficiencia cardiaca congestiva. |
| TW200833670A (en) * | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| AU2008285289A1 (en) | 2007-08-03 | 2009-02-12 | Biomarin Iga Limited | Drug combinations for the treatment of Duchenne muscular dystrophy |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| GB0814728D0 (en) | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
| GB0823140D0 (en) | 2008-12-18 | 2009-01-28 | Astrazeneca Ab | New combination |
| GB201009801D0 (en) | 2010-06-11 | 2010-07-21 | Astrazeneca Ab | Compounds 950 |
| GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| SI2890687T1 (sl) * | 2012-08-30 | 2017-10-30 | Novartis Ag | Soli benzotiazolonske spojine kot agonist beta-2-adrenoceptorja |
| WO2014132205A1 (en) | 2013-02-28 | 2014-09-04 | Novartis Ag | Formulation comprising benzothiazolone compound |
-
2012
- 2012-09-04 JO JOP/2012/0250A patent/JO3192B1/ar active
- 2012-09-05 EA EA201490573A patent/EA022909B1/ru not_active IP Right Cessation
- 2012-09-05 AP AP2014007462A patent/AP3830A/en active
- 2012-09-05 EP EP12770249.6A patent/EP2753609B1/en active Active
- 2012-09-05 JP JP2014529113A patent/JP6130835B2/ja not_active Expired - Fee Related
- 2012-09-05 US US13/603,990 patent/US8933108B2/en not_active Expired - Fee Related
- 2012-09-05 LT LTEP12770249.6T patent/LT2753609T/lt unknown
- 2012-09-05 PH PH1/2014/500399A patent/PH12014500399A1/en unknown
- 2012-09-05 TW TW101132414A patent/TWI555738B/zh not_active IP Right Cessation
- 2012-09-05 HR HRP20170075TT patent/HRP20170075T1/hr unknown
- 2012-09-05 UY UY0001034312A patent/UY34312A/es not_active Application Discontinuation
- 2012-09-05 CN CN201610536836.2A patent/CN106187942B/zh not_active Expired - Fee Related
- 2012-09-05 KR KR1020167007782A patent/KR101800140B1/ko not_active Expired - Fee Related
- 2012-09-05 CU CUP2014000028A patent/CU24303B1/xx unknown
- 2012-09-05 PT PT127702496T patent/PT2753609T/pt unknown
- 2012-09-05 PL PL12770249T patent/PL2753609T3/pl unknown
- 2012-09-05 CN CN201280043386.3A patent/CN103781771B/zh not_active Expired - Fee Related
- 2012-09-05 CA CA2845766A patent/CA2845766A1/en not_active Abandoned
- 2012-09-05 KR KR1020147008777A patent/KR101628585B1/ko not_active Expired - Fee Related
- 2012-09-05 UA UAA201401193A patent/UA114295C2/uk unknown
- 2012-09-05 SI SI201230841A patent/SI2753609T1/sl unknown
- 2012-09-05 AU AU2013200422A patent/AU2013200422C1/en not_active Ceased
- 2012-09-05 BR BR112014004732A patent/BR112014004732A2/pt not_active Application Discontinuation
- 2012-09-05 HU HUE12770249A patent/HUE030530T2/en unknown
- 2012-09-05 SG SG2014013114A patent/SG2014013114A/en unknown
- 2012-09-05 DK DK12770249.6T patent/DK2753609T3/en active
- 2012-09-05 RS RS20161145A patent/RS55468B1/sr unknown
- 2012-09-05 ES ES12770249.6T patent/ES2615052T3/es active Active
- 2012-09-05 WO PCT/IB2012/054580 patent/WO2013035047A1/en not_active Ceased
- 2012-09-05 PE PE2014000312A patent/PE20141993A1/es not_active Application Discontinuation
- 2012-09-05 MY MYPI2014000358A patent/MY163301A/en unknown
- 2012-09-05 MX MX2014002688A patent/MX345405B/es active IP Right Grant
- 2012-09-06 AR ARP120103276A patent/AR087787A1/es unknown
-
2014
- 2014-02-10 TN TNP2014000060A patent/TN2014000060A1/en unknown
- 2014-02-13 ZA ZA2014/01112A patent/ZA201401112B/en unknown
- 2014-02-27 CL CL2014000493A patent/CL2014000493A1/es unknown
- 2014-02-27 IL IL231235A patent/IL231235A/en active IP Right Grant
- 2014-03-04 GT GT201400042A patent/GT201400042A/es unknown
- 2014-03-06 CO CO14048375A patent/CO6900147A2/es not_active Application Discontinuation
- 2014-03-06 CR CR20140114A patent/CR20140114A/es unknown
- 2014-12-10 US US14/566,021 patent/US20150094346A1/en not_active Abandoned
-
2015
- 2015-02-03 ZA ZA2015/00790A patent/ZA201500790B/en unknown
- 2015-08-03 US US14/817,175 patent/US20150336914A1/en not_active Abandoned
- 2015-11-20 US US14/947,458 patent/US20160075670A1/en not_active Abandoned
-
2016
- 2016-06-10 US US15/178,579 patent/US9913828B2/en not_active Expired - Fee Related
-
2017
- 2017-02-02 CY CY20171100153T patent/CY1118585T1/el unknown
- 2017-03-01 JP JP2017038701A patent/JP6340103B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-22 US US15/876,619 patent/US10251868B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02321B (me) | Antivirusna jedinjenja | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| EP2650293A8 (en) | [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof | |
| BR112015020545A2 (pt) | derivado de tetraidroimidazo[1,5-d][1,4]oxazepina | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| FI4159217T3 (fi) | Mek-estäjän ja b-raf-estäjän käsittävä yhdistelmä | |
| AR084824A1 (es) | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas | |
| IN2014KN00948A (enExample) | ||
| EP2639229A3 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
| EP2590655A4 (en) | COMPOUNDS AND METHOD FOR INHIBITING PHOSPHATE TRANSPORT | |
| WO2008147557A3 (en) | Heteroaryl substituted thiazoles and their use as antiviral agents | |
| WO2009080705A3 (en) | Bis-thiazole derivatives, process for their preparation and their use as medicaments | |
| UA99447C2 (ru) | Способ получения силденафила | |
| GB2454615A (en) | Antidiabetic azabicyclo (3.1.0) hexan compounds | |
| ME02576B (me) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| SI2945620T1 (en) | Nitroxyl donors with improved therapeutic index | |
| FI3119911T3 (fi) | Yhdisteitä käytettäväksi alzheimerin taudin hoitamisessa apoe4+/+-potilaissa | |
| AR073117A1 (es) | Derivado de aminometil-fenil-piperidin-1-il-indolil-metanona, inhibidores de la triptasa de mastocitos, composiciones farmaceuticas que lo contienen, metodo de preparacion, compuestos intermediarios y uso del compuesto en el tratamiento de procesos inflamatorios. | |
| WO2011097946A8 (zh) | 含有并环稠合双环的噁唑烷酮化合物及其制备和应用 | |
| CA2873096A1 (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
| JP2017132781A5 (enExample) | ||
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| FR2939667B1 (fr) | Composition d'immunoglobine g comme medicament pour le traitement de l'ictere neonatal par incompatibilite foetomaternelle dans le systeme abo | |
| ME02351B (me) | Derivati 2 -oxo- 1-imidazolidinil imidazotiadiazol | |
| JP2016512541A5 (enExample) |